This information is intended only for healthcare professionals resident in the United Kingdom

Prescribing Information (PI) for Cresemba (isavuconazole), Zavicefta (ceftazidime and avibactam) and Zinforo (ceftaroline fosamil) Great Britain (GB) & Northern Ireland (NI)

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

Great Britain

  • Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion - PI for GB
  • Cresemba (isavuconazole) 100mg Hard Capsules - PI for GB

Northern Ireland

  • Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion and 100mg Hard Capsules - PI for NI

Great Britain

  • Zavicefta (ceftazidime and avibactam) 2g/0.5g powder for concentrate for solution for infusion - PI for GB

Northern Ireland

  • Zavicefta (ceftazidime and avibactam) 2g/0.5g powder for concentrate for solution for infusion - PI for NI

Great Britain

  • Zinforo (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion - PI for GB

Northern Ireland

  • Zinforo (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion - PI for NI

Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion - PI for GB

Cresemba (isavuconazole) 100mg Hard Capsules - PI for GB

Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion and 100mg Hard Capsules - PI for NI

Zavicefta (ceftazidime and avibactam) 2g/0.5g powder for concentrate for solution for infusion - PI for GB

Zavicefta (ceftazidime and avibactam) 2g/0.5g powder for concentrate for solution for infusion - PI for NI

Zinforo (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion - PI for GB

Zinforo (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion - PI for NI

PP-CRB-GBR-1634. July 2022